Condition: Cirrhosis, Liver · Fibrosis, Liver · Sponsor: The Second Affiliated Hospital of Chongqing Medical University
This is a controlled, observational clinical study initiated by investigators to investigate the efficacy and safety of sulfasalazine in the treatment of cirrhosis in patients with cirrhosis. Four cohorts were planned: primary biliary cirrhosis, hepatitis B and C cirrhosis, and alcoholic cirrhosis. The four groups were divided into experimental group and control group, and the experimental group: each group of patients was orally treated sulfasalazine for 12 months, taken three times a day, each time taking 0.5g. The control group did not take sulfasalazine. After 12 months, Observe changes in patients' biochemical and imaging indicators, liver stiffness values, fecal microbiota, and metabolites before and after the use of sulfasalazine.
This description comes directly from the study's public registry record.
Mingli Peng, Doctor · +8613512362906 · 300618@cqmu.edu.cn
Yinghua Lan, Doctor · +8613796050629 · 306346@hospital.cqmu.edu.cn
Always discuss trial participation with your own doctor first.
| Chongqing Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| Chongqing | Chongqing, Chongqing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06293378